{
  "docId": "019de075-3207-70ec-93a8-5bb5ec3d9629",
  "docSlug": "951aacbbe982699d0f743a597a954ece",
  "documentTitle": "OKYO Pharma | Results Presentation Deck | 25 slides",
  "authorId": "okyo-pharma",
  "authorName": "OKYO Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 25,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3207-70ec-93a8-5bb5ec3d9629/15",
  "deckHref": "/decks/019de075-3207-70ec-93a8-5bb5ec3d9629",
  "deckJsonHref": "/decks/019de075-3207-70ec-93a8-5bb5ec3d9629.json",
  "deckAnchorHref": "/decks/019de075-3207-70ec-93a8-5bb5ec3d9629#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.28,
        "x": 0,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ddee4db-9cea-4a22-8216-dde5f505deb3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.65,
        "x": 0.31,
        "y": 0.22
      },
      "kind": "list",
      "text": "Dry-eye patients suffer from corneal neuropathic pain, making their condition more resistant to anti-inflammatory drugs\nNo FDA approved topical treatment for ocular pain\nChemR23 receptor on leukocytes targeted by OK-101 is also expressed on neurons and glial cells in the dorsal root ganglion and spinal cord\nSuch patients would benefit from a drug that comprises anti-inflammatory and neuropathic pain reducing characteristics\nOK-101: a promising candidate for the treatment of both inflammation and pain",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b455d2b-9e3b-46c1-af6a-78fb4cdc0cbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Corneal Neuropathic Pain in Dry Eye Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ff7ec10-3950-4c14-9e6a-258c13fa7cfb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 15,
      "beatId": "382ec2ff-8b63-417f-b320-3ad225890764",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 15-16 highlight the specific issue of corneal neuropathic pain in Dry Eye Disease and its impact.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}